Experience with long-term anticoagulant therapy during the past seven years has been sumnmarized. This report is based on the records of 227 individuals treated as private or outpatient clinic patients for from four weeks to seven years. Where adequate laboratory facilities are available outpatient long-term therapy may be satisfactorily controlled by physicians familiar with the use of anticoagulant drugs. Their correct use will lessen the incidence of thromboembolic episodes in patients who have previously suffered from such complications.
T HE POSSIBILITY of long-term prophylactic and therapeutic use of anticoagulant therapy was a natural sequence to its successful use for acute thromboembolic conditions. This necessitated a marked revision in both the technical and the philosophic approach toward such conditions as recurrent thrombophlebitis, myocardial infarction and hearts in auricular fibrillation which were delivering multiple emboli and numerous additional conditions. From a static and resigned approach in which patient and physician alike awaited with apprehension the possibility of a series of serious or even fatal developments, it was conceivable that a dynamic attack might be at least considered with both physiologic and psychologic advantages. In 1946, one of us1 reported a preliminary experience with the use of Dicumarol in the long-term management of patients with rheumatic heart disease with auricular fibrillation and multiple emboli. It is of interest to record that one of the first patients, a woman who had suffered from 21 recognized emboli prior to anticoagulant therapy, is still alive and active. She was placed on anticoagulant therapy on Nov. 6, 1946, after having had nine emboli to different parts of her body in the previous 10 days. The in June, 1950, after 30 days of abstinence from Dicumarol, the only break in her therapy. This was a saddle embolus to the aortic bifurcation which fortunately disintegrated and descended into the smaller vessels with no ensuing loss of tissue. She resumed anticoagulant therapy and has continued it to date.
In the next year, Nichol and Fassett2 reported their experience with long-term therapy in an attempt to forestall acute myocardial infarction. Additional experience confirming the original reports has subsequently been published by our group and others. 3-s While data regarding such long-term therapy are difficult to evaluate because of the countless variables introduced by the active lives of the individuals, the impression has been that the course of individuals so treated has been favorably affected. It has been clearly demonstrated that long-term anticoagulant therapy is feasible for ambulatory patients in active life, and that such patients can, in many instances, be self-supporting and productive citizens. With the passage of years, additional experience with such patients in private practice and in the New York Hospital Anticoagulant Clinic appears to warrant a summary at this time.
MATERIAL AND METHODS OF STUDY
This report is based on the case records of 227 patients who have been treated with anticoagulant drugs (Dicumarol and Tromexan) on an outpatient basis for a period of four weeks or longer.* Long-* This analysis included experience up to Jan. 1, 1952. Circulation, 'olume IX, June, 1954 823 LONG-TERM ANTICOAGULANT THERAPY term therapy of the patients included in this series was first begun in 1946. A few of these original patients are still under treatment eight years later. Ninety-nine patients have been cared for in the Anticoagulant Clinic of the New York Hospital, and 129 in private practice. One was treated privately initially and later attended the hospital outpatient clinic. The over-all experience thus obtained in the outpatient management of subjects receiving anticoagulant drugs totals 180 years, 124 days. One hundred and eighty-two subjects received Dicumarol during a total of 161 years, 339 days (59,104 days), while 53 subjects received Tromexan during 18 years, 173 days, (6,743 days). Eight subjects received both drugs at differing stages during their treatment.
The conditions treated and the number of patients in each group are shown in table 1, while the distribution of the cases between hospital and private practice is shown in table 2. A minimum of 546 thromboembolic episodes (table 3) had been experienced by 219 patients (the eight patients with glaucoma had not experienced any thromboembolic upset). In 258 instances the episode or episodes occurred just prior to the commencement of treatment, and in 288 instances these episodes antedated treatment, frequently by many years, and occurred during a minimum total of 549 years. Thirteen patients (five with thrombophlebitis, six with rheumatic heart disease, one with a cerebral thrombosis, and one with essential polyangiitis) were accepted for treatment, not because of a recent acute thromboembolic incident, but because of a history of past thromboembolic incidents. Eight patients with effort pain, or more severe coronary insufficiency were treated in the hope of preventing the development of a myocardial infarct. Six of these had previously had one or more myocardial infarcts. In all cases chosen for treatment the object was to prevent the occurrence of further thromboembolic episodes.
The patients selected were all intelligent, cooperative subjects who realized the importance of conscientiously taking the daily dose of drug prescribed for them, and also the necessity for the regular estimation of the prothrombin time. Lack of cooperation on the part of the patient was an indication for the cessation of treatment.
In general the prothrombin time of each patient was estimated once weekly. HIowever, at the start of the outpatient management this was sometimes done twice or even three times weekly, while later, after the patient had been treated for some months and the dosage was stabilized, the interval between prothrombin estimations was increased in a few to 10 or 14 days or, rarely, longer. At each visit the patient was questioned and was examined, if this was indicated. After determination of the prothrombin time, the dosage schedule of Dicumarol or Tromexan for the next one or two weeks was determined. Prothrombin estimations were done in the laboratory by the Quick method, using rabbit lung as the source of thromboplastin. Normal results vary between 14 and 16 seconds. In the majority of patients treated in this series, a prothrombin time of 25 to 30 seconds was considered therapeutically desirable. In some 20 to 25 seconds was selected for a variety of specific reasons. The following points have been determined from the records of each patient: (1) total duration of outpatient treatment; (2) amount of anticoagulant drug used; (3) average daily dose of the anticoagulant drug; (4) number of weeks in which the patient's prothrombin time was (a) less than 20 seconds, (b) between 20 and 24.9 seconds, (c) between 25 and 39.9 seconds, and (d) over 40 seconds; (5) complications resulting from the original disease process or from the treatment with the anticoagulant drugs, and the management of these complications; (6) the management of the problem of oral surgery. All deaths have been analyzed as to cause and as to their possible relationship to the anticoagulant therapy.
Forty-six of the 227 patients were treated as outpatients on two or more occasions, their outpatient course being interrupted by admission to the hospital for some reason, for example the development of a thromboembolic incident, the onset of congestive heart failure, the necessity for an periods of less than 28 days have been included as a number of patients treated on more than one occasion as outpatients had only a short period of treatment between two hospital admissions. operation, or for oral surgery, and other causes. Thirty-two patients had two periods of outpatient treatment, eight had three periods, five had four periods, and one had five periods. Although in some patients the anticoagulant drugs were continued throughout their stay in the hospital, each period of outpatient management has been analyzed separately. There are, therefore, 293 separate periods of outpatient anticoagulant treatment for analysis. In fifteen instances the interval between one hospital admission and the next was less than 28 days, but these periods have been included in the analysis. Details are given in table 4. Twelve subjects have been treated continuously for periods of more than 1000 days. The There was considerable interindividual variation in the average daily requirement of the drug. This is illustrated in table 5, from which it will be seen that the majority of patients required an average of between 40 and 69 mg. of Dicumarol per day. The extremes of dosage, however, ranged from an average of 19 mg. per day to an average of 124 mg. per day. Some patients when treated over a long period did vary in their intraindividual average daily requirement at different stages. However, the majority of patients who received two or more courses of outpatient treatment showed closely comparable average daily requirements for these courses, for example, one patient received 57, 53, 60 and 56 mg. as a daily average during four periods of treatment, while another received 29, 28, 27 and 31 mg. of Dicumarol also during four periods. On the other hand, a few patients did differ markedly in their average daily requirement from one course to the next. For example, one patient treated during two periods required a daily average of 113 mg. of Dicumarol during the first period and 79 mg. during the second. It is difficult in retrospect to explain this difference. 
Adequacy of Treatment
In spite of the variations just referred to, the adequacy of the anticoagulant treatment is reflected in the analysis of the prothrombin times recorded for each patient and in the incidence of thrombotic or embolic complications. As previously stated, the results of the prothrombin times have been grouped into four grades for analysis. A time of 25 seconds was considered to be the lower limit at which the anticoagulant treatment would be optimal. Prolongation of the prothrombin time to between 20 and 24.9 seconds was possibly adequate under most circumstances, but might not give maximum protection from thromboembolic complications. A prothrombin time of less than 20 seconds was considered to be therapeutically inadequate and to afford little . 826 JOHN TULLOCH AND IRVING S. WRIGHT 
Complications
Complications did occur, both of a thrombotic and hemorrhagic nature. Twentysix out of 227 patients (11.4 per cent) experienced a total of 40 definite or possible thromboembolic episodes, while 43 patients (18.9 per cent) suffered 70 hemorrhagic complications. In addition, 33 subjects (14.5 per cent) developed a very high prothrombin time (well over 40 seconds) on 51 occasions without the occurrence of bleeding. Thromboembolic Complications. These developed in four groups of patients: those with thrombophlebitis, myocardial infarction, pulmonary emboli, and rheumatic heart disease with emboli. Details are given in table 8. In 18 of the 40 incidents, an exact diagnosis could not be reached, but the incident was thought to represent a thrombotic or embolic episode. In 13 instances the prothrombin time was estimated on the day of the episode, and in 14 this was done within one to five days prior to the occurrence of the complication. In the remaining instances this information is not available. Details are given in table 9. If the figures for the two parts of the table are combined, it will be seen that as many as half of the thromboembolic complications'3 occurred while the prothrombin time was theoretically adequate to protect the patient against these episodes, and that three occurred while the prothrombin time was excessively prolonged. The diagnosis was not clear in 12 of these 16 episodes; there was considerable doubt in the mind of the physician in charge of the case as to the exact nature of the upset experienced by the patient. In one other instance a phlebitis was probably of a traumatic nature as it developed in the vein used for cardiac cathe- terization one day following that procedure. Three definite episodes, phlebitis, pulmonary infarction and cerebral embolism, occurred at levels of prothrombin times of 31, 37 and 27 seconds, respectively. Five thromboembolic episodes, one of a doubtful nature, occurred when the prothrombin time was less than 20 seconds, and six episodes, two of which were of a doubtful nature occurred at prothrombin times of between 20 and 24.9 seconds. These findings indicate that at no level of prolongation of the prothrombin time was complete protection provided from thromboembolic episodes. When the prothrombin time ranged between 25 and 39.9 seconds, the episodes were often vague and not clearly of a thrombotic nature, but the majority of the episodes occurring when the prothrombin time was less than 24.9 seconds were quite definite. Nevertheless, even if doubtful, they were listed as thromboembolic complications. (table 10) . Many types of bleeding complications were encountered. Only cases of gross hemorrhage have been listed. No consistent search was made for microscopic hematuria. Subcutaneous ecchymoses and hematomata were the most common occurrences. In 60 instances the prothrombin time was estimated either on the day on which bleeding began or within two days before or after the onset of bleeding. The relationship of the bleeding to the prothrombin time is shown in table 11. The majority of these episodes occurred when the prothrombin time was over 25 seconds; 27 episodes when it was between 25 and 39.9 seconds and 19 when it was over 40 seconds. Only three patients showed evidence of bleeding when the pro- thrombin time was less than 20 seconds; in one of these three patients hematemesis occurred during a bout of acute gastritis, in one ecchymoses developed on the legs following trauma, and in one patient ecchymoses appeared spontaneously on the legs. Eleven episodes occurred when the prothrombin time was between 20 and 24.9 seconds. In these the prothrombin deficiency was not necessarily the sole factor responsible for the bleeding, for example, hematomata developed after injury and injection, and hematuria after catheterization. Only cerebral hemorrhage was of serious consequence in this group. It accounts for the sole death due to hemorrhage in patients still receiving anticoagulant drugs.
Taking the number of bleeding complications occurring respectively at prothrombin time between 25 and 39.9 seconds and over 40 seconds in relationship to the number of weeks in which the prothrombin time was known to be at these levels, 3987 and 517 weeks respectively, it is evident that, although bleeding may occur when the prothrombin time is between 25 and 39.9 seconds, it is relatively more common when the prothrombin time is over 40 seconds. Seven bleeding complications occurred in six patients receiving Tromexan; the remaining patients were receiving Dicumarol. This is approximately in proportion to the duration of treatment with the two drugs.
Treatment of the bleeding consisted in most cases in the adjustment or temporary cessation of Dicumarol (or Tromexan) administration until the bleeding had ceased. They were not stopped when the bleeding was slight and the prothrombin time low, for example, subcutaneous ecchymoses, slight bleeding from gums or hemorrhoids. Eleven patients received specific treatment to hasten the return of the prothrombin content of their blood to more normal levels. Two patients received vitamin Ki and nine received water soluble vitamin K. Two of the latter nine patients were also transfused with whole fresh blood, receiving 500 cc. and 1500 cc., respectively.
High Prothrombin Time without Bleeding. A further feature encountered during the out- I I Associated with a hiatus hernia. patient anticoagulant treatment was the occurrence of excessive prolongation of the prothrombin time without associated bleeding. This occurred in 33 patients on 51 occasions. Twenty-nine patients who were 829 receiving Dicumarol developed excessive prolongation of the prothrombin time on 46 occasions, while this developed five times in four patients who were receiving Tromexan. Again this incidence is in proportion to the duration of treatment with the two drugs. In these, as in the patients exhibiting bleeding, the Dicumarol (or Tromexan) was temporarily stopped until the prothrombin time had fallen to a safe level. On 23 occasions (21 related to Dicumarol administration, and two to Tromexan), treatment with water soluble vitamin K or vitamin K1 was also given to hasten the fall in prothrombin time. Administration of Vitamin K and Vitamin K1. Twenty-four subjects were treated with water soluble vitamin K on 29 separate occasions, and five subjects received vitamin K1 on six occasions. One patient was treated with both vitamin K and vitamin K1 during one episode. Two patients were treated on more than one occasion; one patient was very unstable in this regard, receiving vitamin K on five separate occasions, and the other received vitamin K1 on two occasions and vitamin K on a third. The indications for administration of either drug were, (1) an excessive prolongation of the prothrombin time without bleeding on 23 occasions; (2) bleeding on 11 occasions; (3) one episode finally recorded as renal infarction, or renal stone which produced bleeding with a prothrombin time of 51 seconds (control 16 seconds). The bleeding episodes which were treated were as follows: Prolonged excessive menstrual flow (prothrombin time 46.6 seconds, 60 seconds, and 55 seconds during the three weeks prior to menstruation), intracranial bleeding (prothrombin time 41 seconds), ecchymoses (prothrombin time 16.2 seconds), hematemesis (prothrombin time 19.9 seconds), hematoma following injection (prothrombin time 38 seconds), bleeding from nose and gums (prothrombin time 98 seconds), cerebral hemorrhage and melena (prothrombin time 51 seconds), hematemesis and melena (prothrombin time 26 seconds), cerebral hemorrhage (only death from hemorrhage) (prothrombin time 24 seconds), acute hemorrhagic glaucoma (prothrombin time 78 seconds), and melena (prothrombin time 215 seconds).
The last two conditions were treated with vitamin K1.
In 21 patients water soluble vitamin K was given as a single intravenous injection, the effective dose ranging from 60 to 154 mg. One patient with hematemesis and melena from a hiatus hernia, received 72 mg. of vitamin K in a single intravenous injection and was transfused with 1500 cc. of fresh blood.
In 12 instances the prothrombin time was estimated on the day following a single dose of vitamin K and in seven it had fallen to within the normal range (table 12) .
The vitamin K1 was given by mouth. The doses were 1.0 Gm. on three occasions, and 750 mg. on a fourth. In the fifth case the patient received 100 mg. at the onset and 500 mg. six and one-half hours later. One patient with acute hemorrhagic glaucoma who received 1 Gm. by mouth also received 72 mg. of vitamin K intravenously. In four of these patients the prothrombin time was estimated on the day following the vitamin K1 administration and in all it was greatly reduced (table 12) . It has been found in other studies that there is usually a marked reduction from an elevated prothrombin time within four to eight hours after the oral administration of 1 Gm. orally 1 Gm. orally 750 mg. orally 830 vitamin K1, or vitamin KI1 oxide in doses of 100 to 500 mg.
Oral Surgery. Fourteen patients required extraction of teeth on 15 occasions. In 13 instances the patient's prothrombin time was allowed to return to normal or near normal before extraction was undertaken. Administration of Dicumarol was therefore stopped in each case several days before the oral surgery was to be undertaken; four days ill most cases, but eight days in one patient. In three patients the prothrombin time on the day of the extraction was known; in two it was normal, and in the third it was 19 seconds (control 16 seconds). In the other cases, the prothrombin time recorded one to five days before the oral surgery was either near the normal level or in the low therapeutic range. No undue bleeding occurred in these cases. In one patient no opportunity for proper preparation was available and he had the high prothrombin time of 51 seconds (control 15.5 seconlds) when extraction was performed. The tooth sockets oozed blood for three days. In one patient the details of Dicumarol dosage and of the prothrombin times are not known, but it was recorded that the tooth sockets were sutured and that there was no undue bleeding.
Potelltially serious thromboembolic complications occurred in one of the patients in which the prothrombin time was allowed to return to normal before dental surgery; no Dicumarol had been taken for eight days. This patient suffered from rheumatic heart disease with auricular fibrillation and was receiving long-term anticoagulant therapy because of previous multiple emboli. Her experience illustrates the risk of further emboli when anticoagulant therapy is discontinued in these cases. The delay of eight days in undertaking the oral surgery was unexpected and unfortunate. In spite of restarting Dicumarol on the day on which the oral surgery was performed, a cerebral embolus developed after two days when the prothrombin time was 18.1 seconds (control 15.2 seconds), and four days later a second embolus lodged at the bifurcation of the right brachial artery (prothrombin time 18.3 seconds, control 13.7 seconds). Following adequate anticoagulant therapy, no further emboli occurred and these apparently disintegrated without serious residual.
Other Complications. Incidents of importance occurred in 19 patients during the course of their outpatient management. Seven were admitted to the hospital on 10 occasions for treatment of heart failure. Four patients were admitted for operations; two for mitral commissurotomy, one for a cholecystectomy, one for an exploratory laparotomy, and one was admitted with a renal calculus. Anticoagulant therapy was temporarily discontinued prior to each operation. No untoward complications developed in association with these episodes. A chalazion was excised from one patient after Dicumarol had been stopped for five days and while the prothrombin time was 16.5 seconds (control 15 seconds). A hyperkeratotic patch was removed from the hand of another patient by electrofulguration while his prothrombin time was 30.9 seconds (control 14.8 seconds). Two patients with menstrual irregularity were admitted for a diagnostic dilatation and curettage. This was carried out in each case after the prothrombin time had fallen to within the normal range. One pregnant woman was delivered without ill effect while her prothrombin time was 32 seconds. Two patients developed psychiatric disorders and Dicumarol administration had to be temporarily stopped because of the difficulty of controlling the therapy. One The two patients who died suddenly had rheumatic heart disease, and, when last estimated, the prothrombin time of each had been within the therapeutic range (28.7 seconds, control 14.7 seconds, two days before death, and 30.5 seconds, control 15.5 seconds, :. o~c .Ẽ _________u ;T ch3 * + * + * + '' t * t * t * + Rheumatic heart 3 2tl 10 10 00 00 02 0 disease Myocardial in-0 0 1 0100000000 0 farction Pulmonary embo-1 10 00 00 00 00 00 0 lism Thrombophlebitis 0 00 0 01 00 20 00 0 Cerebral throm-O 00 00 00 0 00 0 10 0 bosis Arterial throm-1 00 00 00 00 00 00 0 bosis and embolism 5 4 2 11 11 00 20 12 0 9 3 2 1 2 1 2 * On anticoagulants at time of death.
t Off anticoagulants before death. $ Anticoagulant status of these two patients unknown. six days before death, respectively). There was no reason to suspect from their previous course that these values were materially altered at the time of death. Three died in congestive heart failure in the hospital while being adequately treated with anticoagulants. The sixth patient with rheumatic heart disease died of myocardial infarction. The patient treated because of pulmonary emboli died in congestive heart failure. Two other patients died while in the hospital and on anticoagulant therapy; one with thrombosis of the hepatic veins died from liver failure, and the other, with auricular fibrillation and arterial emboli, died in congestive heart failure. Of the two patients who were being treated because of myocardial infarction and who died, one died from what was thought to be a fresh infarction. His prothrombin time on the day prior to death was not optimal, being 20 seconds (control 16 seconds). The other patient died of a cerebral hemorrhage. Two days before death, his prothrombin time was 24 seconds (control 16 seconds). It is unlikely that the reduction in the prothrombin content of the blood was responsible for the initiation of the cerebral bleeding, but it undoubtedly contributed to the severity of the bleeding once this had occurred. The cause of death in the eight patients dying after discontinuing anticoagulant treatment varied. Two patients who had been treated for phlebitis died of malignant disease; one had previously developed a hemiplegia. Two patients with rheumatic heart disease died in congestive heart failure. One patient died of a recurrence of myocardial infarction, and a second patient who had previously sustained a myocardial infarction developed a cerebral accident and died. One patient treated because of pulmonary emboli died in congestive heart failure, and one patient treated for a cerebral thrombosis died of pneumonia. The one patient in whom the anticoagulant status at the time of death is not known had been admitted to a hospital in psychotic state and her dosage was not known. She had advanced rheumatic heart disease, and died in congestive heart failure about two weeks after developing a pulmonary embolus.
